drugset
drugset / Trial / NCT07150845

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

NCT07150845 ↗

Phase 2 Active not recruiting 120 enrolled Evommune, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Timeline

Start
2025-08-26
Primary completion
2026-07
Completion
2026-07

Outcome

Missed primary endpoint

release “this trial of EVO756 did not meet its primary endpoint” evommune.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject EVO756 Unknown — Oral

Indications

atopic eczema